144 related articles for article (PubMed ID: 19373657)
1. N9986: a phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia.
Kay NE; Shanafelt TD; Call TG; Wu W; Laplant BR
Leuk Lymphoma; 2009 Apr; 50(4):588-92. PubMed ID: 19373657
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.
Chanan-Khan A; Miller KC; Musial L; Lawrence D; Padmanabhan S; Takeshita K; Porter CW; Goodrich DW; Bernstein ZP; Wallace P; Spaner D; Mohr A; Byrne C; Hernandez-Ilizaliturri F; Chrystal C; Starostik P; Czuczman MS
J Clin Oncol; 2006 Dec; 24(34):5343-9. PubMed ID: 17088571
[TBL] [Abstract][Full Text] [Related]
3. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.
Byrd JC; Peterson BL; Gabrilove J; Odenike OM; Grever MR; Rai K; Larson RA;
Clin Cancer Res; 2005 Jun; 11(11):4176-81. PubMed ID: 15930354
[TBL] [Abstract][Full Text] [Related]
4. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL).
Chanan-Khan A; Miller KC; Takeshita K; Koryzna A; Donohue K; Bernstein ZP; Mohr A; Klippenstein D; Wallace P; Zeldis JB; Berger C; Czuczman MS
Blood; 2005 Nov; 106(10):3348-52. PubMed ID: 16051743
[TBL] [Abstract][Full Text] [Related]
5. Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Costa LJ; Fanning SR; Stephenson J; Afrin LB; Kistner-Griffin E; Bentz TA; Stuart RK
Leuk Lymphoma; 2015 Mar; 56(3):645-9. PubMed ID: 25130476
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.
Badoux XC; Keating MJ; Wen S; Wierda WG; O'Brien SM; Faderl S; Sargent R; Burger JA; Ferrajoli A
J Clin Oncol; 2013 Feb; 31(5):584-91. PubMed ID: 23270003
[TBL] [Abstract][Full Text] [Related]
7. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
[TBL] [Abstract][Full Text] [Related]
9. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Chanan-Khan AA; Zaritskey A; Egyed M; Vokurka S; Semochkin S; Schuh A; Kassis J; Simpson D; Zhang J; Purse B; Foà R
Lancet Haematol; 2017 Nov; 4(11):e534-e543. PubMed ID: 28958469
[TBL] [Abstract][Full Text] [Related]
11. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
12. A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia.
Maddocks K; Ruppert AS; Browning R; Jones J; Flynn J; Kefauver C; Gao Y; Jiang Y; Rozewski DM; Poi M; Phelps MA; Harper E; Johnson AJ; Byrd JC; Andritsos LA
Leuk Res; 2014 Sep; 38(9):1025-9. PubMed ID: 25082342
[TBL] [Abstract][Full Text] [Related]
13. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.
Wendtner CM; Hillmen P; Mahadevan D; Bühler A; Uharek L; Coutré S; Frankfurt O; Bloor A; Bosch F; Furman RR; Kimby E; Gribben JG; Gobbi M; Dreisbach L; Hurd DD; Sekeres MA; Ferrajoli A; Shah S; Zhang J; Moutouh-de Parseval L; Hallek M; Heerema NA; Stilgenbauer S; Chanan-Khan AA
Leuk Lymphoma; 2012 Mar; 53(3):417-23. PubMed ID: 21879809
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
Farooqui MZ; Valdez J; Martyr S; Aue G; Saba N; Niemann CU; Herman SE; Tian X; Marti G; Soto S; Hughes TE; Jones J; Lipsky A; Pittaluga S; Stetler-Stevenson M; Yuan C; Lee YS; Pedersen LB; Geisler CH; Calvo KR; Arthur DC; Maric I; Childs R; Young NS; Wiestner A
Lancet Oncol; 2015 Feb; 16(2):169-76. PubMed ID: 25555420
[TBL] [Abstract][Full Text] [Related]
15. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.
Chen CI; Bergsagel PL; Paul H; Xu W; Lau A; Dave N; Kukreti V; Wei E; Leung-Hagesteijn C; Li ZH; Brandwein J; Pantoja M; Johnston J; Gibson S; Hernandez T; Spaner D; Trudel S
J Clin Oncol; 2011 Mar; 29(9):1175-81. PubMed ID: 21189385
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group.
Bergmann MA; Goebeler ME; Herold M; Emmerich B; Wilhelm M; Ruelfs C; Boening L; Hallek MJ;
Haematologica; 2005 Oct; 90(10):1357-64. PubMed ID: 16219572
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
[TBL] [Abstract][Full Text] [Related]
18. Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics.
Vitale C; Falchi L; Ten Hacken E; Gao H; Shaim H; Van Roosbroeck K; Calin G; O'Brien S; Faderl S; Wang X; Wierda WG; Rezvani K; Reuben JM; Burger JA; Keating MJ; Ferrajoli A
Clin Cancer Res; 2016 May; 22(10):2359-67. PubMed ID: 26733610
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.
James DF; Werner L; Brown JR; Wierda WG; Barrientos JC; Castro JE; Greaves A; Johnson AJ; Rassenti LZ; Rai KR; Neuberg D; Kipps TJ
J Clin Oncol; 2014 Jul; 32(19):2067-73. PubMed ID: 24868031
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.
Wendtner CM; Hallek M; Fraser GA; Michallet AS; Hillmen P; Dürig J; Kalaycio M; Gribben JG; Stilgenbauer S; Buhler A; Kipps TJ; Purse B; Zhang J; De Bedout S; Mei J; Chanan-Khan A
Leuk Lymphoma; 2016; 57(6):1291-9. PubMed ID: 26763349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]